The original success of Sildenafil undeniably transformed the pharmaceutical landscape, but investing in companies heavily reliant on unbranded versions presents a complex picture. While early earnings were significant, the expiration of patents and the appearance of discounted alternatives have eroded sales. Thus, a thorough evaluation of current